Compare ANL & CEPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ANL | CEPV |
|---|---|---|
| Founded | 2004 | 2021 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.9M | 326.2M |
| IPO Year | 2022 | N/A |
| Metric | ANL | CEPV |
|---|---|---|
| Price | $8.28 | $10.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 459.6K | 99.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $10.11 |
| 52 Week High | $12.09 | $10.35 |
| Indicator | ANL | CEPV |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 39.58 |
| Support Level | $1.36 | N/A |
| Resistance Level | $12.09 | $10.35 |
| Average True Range (ATR) | 0.82 | 0.03 |
| MACD | -0.47 | -0.00 |
| Stochastic Oscillator | 36.73 | 23.53 |
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Cantor Equity Partners V Inc is a blank check company.